Home Newsfeeds Silo Pharma Advances Clinical Study Analyzing Effects Of Psilocybin On Inflammation

Silo Pharma Advances Clinical Study Analyzing Effects Of Psilocybin On Inflammation

Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders

byBenzinga Newsdesk

January 10, 2023

1 minute read

Parkinson’s disease, bipolar disorder, and chronic pain targeted in study

Study aims to support psilocybin as a potential therapeutic for inflammatory disorders

What’s Going On With Harley-Davidson Shares After Q1 Results?

By Nabaparna Bhattacharya

April 25, 9:44 AM

Harley-Davidson shares dip despite beating Q1 earnings and revenue estimates, citing planned motorcycle shipment decrease.

HOG

Innovative Eyewear, Inc. Announces $1.025M Definitive Agreement For The Issuance And Sale Of 4,200,822 Shares Of Its Common Stock At A Purchase Price Of $0.244 Per Share

By Benzinga Newsdesk

April 29, 8:02 AM

Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ:LUCY, LUCYW)))), the developer and seller of smart eyewear, today announced that it has entered into a

LUCY

Teva Pharma’s Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo

By Vandana Singh

August 2, 10:00 AM

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q2 sales reached $3.88 billion, up 2% Y/Y (4% on constant currency), slightly beating the

TEVA

Procter & Gamble Q1 Earnings Beat Estimates; Cuts FY23 All-In Sales Outlook On FX Headwinds

By Shivani Kumaresan

October 19, 8:33 AM

Procter & Gamble Co (NYSE:PG) reported first-quarter FY23 sales growth of 1% year-on-year to $20.61 billion, beating the consensus of $20.44…

Silo Pharma Advances Clinical Study Analyzing Effects Of Psilocybin On Inflammation

Related Posts

What’s Going On With Harley-Davidson Shares After Q1 Results?

Innovative Eyewear, Inc. Announces $1.025M Definitive Agreement For The Issuance And Sale Of 4,200,822 Shares Of Its Common Stock At A Purchase Price Of $0.244 Per Share

Teva Pharma’s Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo

Procter & Gamble Q1 Earnings Beat Estimates; Cuts FY23 All-In Sales Outlook On FX Headwinds